3+ hour, 7+ min ago   (660+ words) During a virtual event, Aditya Bardia, MD, MPH and participants weigh elacestrant and imlunestrant, comparing real-world adverse effects and efficacy. In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors (AI), the landscape of…...

1+ mon, 4+ day ago   (471+ words) Explore groundbreaking FDA approvals in oncology for 2025, enhancing treatment options for breast cancer, lung cancer, and rare tumors. The oncology landscape in 2025 was defined by significant regulatory milestones, with the FDA approving several novel agents that reinforce the paradigm of…...

1+ mon, 2+ week ago   (495+ words) The test, developed by Astrin Biosciences, utilizes deep proteomic profiling and a machine learning classifier to identify cancer-specific protein signatures in plasma. The central challenge addressed is the significant limitation of mammography, which has a sensitivity as low as 30% in…...

1+ mon, 2+ week ago   (443+ words) Findings presented at the 2025 San Antonio Breast Cancer Symposium showed that in cohort 1, the overall response rate (ORR) was higher in patients with RAD51-low (n = 41) vs -high (n = 14) tumors, at 68.3% (95% CI, 53%-80.4%) vs 21.4% (95% CI, 4.7%-50.8%), resulting in a difference of 46.9% (odds ratio…...

1+ mon, 3+ week ago   (365+ words) Discover the latest breakthroughs in oncology from major conferences, including significant findings in breast cancer and multiple myeloma treatments. Welcome to this week's edition of The Targeted Pulse, your weekly wrap-up of the top developments in oncology. This week, we…...

1+ mon, 3+ week ago   (573+ words) New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use. Results from an ongoing study examining patients at high risk for developing both breast and ovarian cancer with the…...

1+ mon, 3+ week ago   (193+ words) Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ... Patients were randomly assigned 1:1 to receive alpelisib at 300 mg in combination with fulvestrant at 500 mg or…...

2+ mon, 4+ day ago   (230+ words) Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies. The field of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) testing is experiencing rapid technological advancement, with new assays demonstrating increasing…...

2+ mon, 5+ day ago   (240+ words) In an interview with Targeted Oncology ", Stefania Morganti, MD, PhD, research fellow at the Dana-Farber Cancer Institute, addressed the current clinical utility and inherent limitations of using ... In an interview with Targeted Oncology, Stefania Morganti, MD, PhD, research fellow at…...

2+ mon, 6+ day ago   (314+ words) Emerging research highlights the challenges and potential of ctDNA in managing minimal residual disease in breast cancer, paving the way for innovative treatment strategies. The presence of minimal residual disease (MRD), specifically circulating tumor DNA (ctDNA) positivity, in patients achieving…...